Weekly Recap: Cash to fund potential IMVT-1402 launch and 5% stock drop
Immunovant Inc (NASDAQ:IMVT) said cash fell to $797.8M on June 30 from $902.1M but should fund operations through a potential commercial launch of IMVT-1402 for Graves’ disease, while shares slid about 5% after results and the company reported a 57-patient randomized, double-blind CLE trial with a…